Dow futures gain on President Donald Trump’s new stance on stimulus. Stocks finished sharply higher Wednesday after Trump said he would consider alternative aid measures such as a new round of stimulus checks, support for airlines, and the Paycheck Protection Program.

In the last episode of Mad Money, Jim Cramer said that when the president tweets something that tanks the stock market, it’s a mistake to sell, because President Trump hates lower stock prices and almost always reverses himself.

TheStreet’s Katherine Ross and Cramer are on Street Lightning talking about buying Alphabet stock, alternatives to the stimulus package, and Trump’s tweets.

Alphabet Stock: Buy or Sell? 

A House panel proposed to limit the power and influence of the tech giants including Amazon  (AMZN) – Get Report, Facebook  (FB) – Get Report, Apple  (AAPL) – Get Report, and Alphabet Inc.  (GOOGL) – Get Report, the parent company of Google. The recommendations from the House antitrust subcommittee could lead to the breakup of tech companies if approved by Congress.

On Tuesday, Google  (GOOGL) – Get Report announced that the G Suite brand will be replaced by Google Workspace as the new name for its package of business tools. The rebranding comes in parallel with the Google features such as having a video chat display at the corner of a document-editing window.

Cramer doesn’t find this concerning, saying “I know that the market is punishing Alphabet and I think that’s crazy.” He advises investors to buy the Alphabet stock which would be “fantastic” if the company was broken up.

Alternatives to a Stimulus Package

President Donald Trump said on Wednesday that he may consider alternative stimulus measures, which may include a paycheck protections program. That would be key for

In 2018, Google reorganized many of its balkanized health efforts under one roof. 

Under the name Google Health, it’s now a team of just under 600, Business Insider has learned, with a bold mission to organize the world’s health information. Many of its scientists would like to see artificial intelligence “democratize” access to care, and build search tools help doctors sift through medical information swiftly.

But healthcare is a big and complicated industry.

Google Health’s work with search and clinical tools is promising, but it’s early and the group leans heavily on other parts of Google for partnerships. It’s not sure how it’ll work with Alphabet’s Verily, a life sciences company that’s banged heads with the Google Health team before. And its employees aren’t confident in its ability to execute, according to interviews and internal documents seen by Business Insider.

While Google Health has struck up deals to work with large health systems such as Ascension and Stanford Medicine over the past two years, talks with some other major players including CVS Health and The Gates Foundation have fallen apart along the way, Business Insider has learned. Experts within the healthcare industry are still confused over what Google Health actually does. And pressure is mounting on Google Health to finally get something off the ground besides promising research. 

Over the past eight weeks, Business Insider got behind the scenes of Google’s secretive health business.

Here’s an inside look at what Google Health has been up to for the past two years, how Alphabet’s healthcare trio — Verily, Google Cloud, and Google Health — function, and what’s ahead for Google’s team of former FDA commissioners, Obama advisers, and surgeon-scientists.

Subscribe to Business Insider to read the full story:

Are you a Google insider with more to share? Contact Hugh Langley using

Jason Kempin | Getty Images Entertainment | Getty Images

(This story is for CNBC PRO subscribers only.)

Here are the biggest calls on Wall Street on Tuesday:

Berenberg initiated Bristol-Myers as buy

Berenberg initiated the pharmaceutical company as buy and said it’s bullish on the company’s pipeline and said Bristol Myers valuation is “attractive.”

“We forecast growth in line with peers. With its pipeline upside and reinvention potential, the current significant valuation discount is undeserved. Our enterprise value/net present value valuation which encompasses the longer-term erosion profile indicates valuation is attractive.”

Argus upgraded Darden to buy from hold

Argus upgraded the restaurant hospitality company and owner of brands like Olive Garden and said it thinks the company has “turned the corner” and is benefiting from dining rooms re-opening and expanded takeout options.

“Management expects further progress in the second quarter, with the comp decline moderating to 18%, EBITDA of $200-$215 million, and EPS of $0.65-$0.75. We think this guidance is achievable as the company has now reopened more than 90% of its restaurant dining rooms (albeit at limited capacity), and continues to benefit from efforts to expand takeout and delivery orders and simplify its menu. We also expect Darden to continue its record of positive earnings surprises over the past six quarters.”

Source Article